%0 Journal Article
%T Antibody-Mediated Rejection: An Evolving Entity in Heart Transplantation
%A Sharon Chih
%A Andrzej Chruscinski
%A Heather J. Ross
%A Kathryn Tinckam
%A Jagdish Butany
%A Vivek Rao
%J Journal of Transplantation
%D 2012
%I Hindawi Publishing Corporation
%R 10.1155/2012/210210
%X Antibody-mediated rejection (AMR) is gaining increasing recognition as a major complication after heart transplantation, posing a significant risk for allograft failure, cardiac allograft vasculopathy, and poor survival. AMR results from activation of the humoral immune arm and the production of donor-specific antibodies (DSA) that bind to the cardiac allograft causing myocardial injury predominantly through complement activation. The diagnosis of AMR has evolved from a clinical diagnosis involving allograft dysfunction and the presence of DSA to a primarily pathologic diagnosis based on histopathology and immunopathology. Treatment for AMR is multifaceted, targeting inhibition of the humoral immune system at different levels with emerging agents including proteasome and complement inhibitors showing particular promise. While there have been significant advances in our current understanding of the pathogenesis, diagnosis, and treatment of AMR, further research is required to determine optimal diagnostic tools, therapeutic agents, and timing of treatment. 1. Introduction Antibody-mediated rejection (AMR) is a diagnostic and therapeutic challenge in human heart transplantation. Although the true incidence of AMR is unknown, it has been reported in 10¨C20% of patients after heart transplant, typically occurring within a few months after transplant [1, 2]. Late occurrences are, however, not uncommon with one study reporting 25% of AMR cases occurring more than one year after transplantation [1]. A diagnosis of AMR portends a poorer prognosis with an increased incidence of allograft dysfunction, mortality, and cardiac allograft vasculopathy (CAV) [3]. AMR was first described as a clinical entity in 1987 by Herskowitz et al. who identified a subset of heart transplant patients with arteriolar vasculitis and poor outcomes [4]. Hammond et al. subsequently showed that vascular rejection was associated with antibody deposition and complement activation [5]. In 2005, the International Society for Heart and Lung Transplant (ISHLT) published specific guidelines for the diagnosis of AMR [6]. An updated consensus was released in 2011, including a separate companion document detailing the working formulation for the pathologic diagnosis of AMR [7, 8]. This paper will discuss the current understanding of AMR, focussing on pathogenesis, diagnosis, and treatment. 2. Pathogenesis AMR occurs due to a humoral immune response with antibodies binding to endothelium on the transplanted heart [5]. The antibodies are typically directed against human leukocyte antigen (HLA) class I
%U http://www.hindawi.com/journals/jtrans/2012/210210/